Newpath Partners is a multi-stage life sciences and healthcare venture capital firm based in Boston, MA. The firm partners with leading academic scientists at the earliest stages of company formation to translate scientific discoveries into transformative therapies.
80% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 2 prior). Average disclosed round size is $111.6M (across 21 rounds with reported amounts).
Portfolio
15
Fund Size
$350M
Top Stage
Series B
Last 12 Mo
1
Team
BL
Ben L.
Investor
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
25 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Create Medicines | Series B | $122M | May 2026 |
| Create Medicines | Series B | $122M | Jan 2026 |
 Metsera | Series B | $215M | Jan 2026 |
| PPrime Medicine Inc | Series A | — | Jan 2025 |
| Metsera | Series B | — | Nov 2024 |
 Leal Therapeutics | Series B | $45M | Oct 2024 |
 Autobahn Therapeutics | Series C | $100M | Jul 2024 |
 Autobahn | Series C | $100M | Jul 2024 |
| NnChroma | Unknown | $75M | Jan 2024 |
| Leal Therapeutics | Seed | $45M | Jan 2024 |
 Magnet Biomedicine | Series A | $50M | Sep 2023 |
 Myeloid Therapeutics | Series C | $73M | May 2023 |
 Orbital Therapeutics | Series A | $270M | Apr 2023 |
 Chroma Medicine | Series B | $135M | Mar 2023 |
| Create Medicines | Series A | $73M | Jan 2023 |
| Myeloid Therapeutics | Series A | $73M | Jan 2023 |
| Chroma Medicine | Seed | $125M | Nov 2021 |
 Neumora Therapeutics, Inc. | Series A | — | Oct 2021 |
| KKojin Therapeutics | Series A | $60M | Jun 2021 |
| Myeloid Therapeutics | Unknown | $50M | Jan 2021 |
| Neumora Therapeutics, Inc. | Series B | $112M | — |
| PPrime Medicine Inc | Series B | — | — |
 Exo Therapeutics | Series B | $78M | — |
 YourBio Health | Unknown | $21M | — |
| Neumora Therapeutics, Inc. | Series A | $400M | — |
Top Co-Investors
ARCH Venture Partners18 shared
Alexandria Venture Investments12 shared
F-Prime Capital7 shared
8VC6 shared
Casdin Capital6 shared
GV6 shared
Moore Strategic Ventures5 shared
Wellington Management5 shared
Mubadala Ventures5 shared
Cormorant Asset Management4 shared
T. Rowe Price4 shared
The Invus Group, LLC4 shared
Atlas Venture3 shared
Omega Funds3 shared
Sofinnova Partners3 shared
Altitude Life Science Ventures3 shared
Samsara BioCapital3 shared
Polaris Partners3 shared
Primary Venture Partners2 shared
Euclidean Capital2 shared
Last updated: 20 October 2026